The total return over the past 12 months is -57.21% vs. +16.94% for the S&P 500. So far it's up -66.47% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (57.21%) | (86.31%) | (81.13%) | N/A | N/A | N/A |
| Total Return CAGR | (57.21%) | (86.31%) | (81.13%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Kalaris Therapeutics Inc (KLRS)
| Year | Start price | End price | KLRS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.44 | $2.83 | (66.47%) | +14.51% | (80.98%) |
| 2025 | $222.18 | $8.44 | (96.20%) | +17.72% | (113.92%) |
| 2024 | $359.61 | $222.18 | (38.22%) | +24.89% | (63.11%) |
| 2023 | $2,713.77 | $359.61 | (86.75%) | +26.19% | (112.94%) |
| 2022 | $6,845.26 | $2,713.77 | (60.36%) | (18.17%) | (42.19%) |
| 2021 | $20,334.76 | $6,845.26 | (66.34%) | +28.74% | (95.08%) |
| 2020 | $299.52 | $20,334.76 | +6689.12% | +18.37% | +6670.75% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
